VRTX Jan 2024 155.000 call
| Previous close | 175.00 |
| Open | 175.00 |
| Bid | 145.00 |
| Ask | 154.50 |
| Strike | 155.00 |
| Expiry date | 2024-01-19 |
| Day's range | 175.00 - 175.00 |
| Contract range | N/A |
| Volume | |
| Open interest | 20 |
- Zacks
Vertex Pharmaceuticals (VRTX) Gains As Market Dips: What You Should Know
In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $313.57, marking a +0.56% move from the previous day.
- Motley Fool
3 Smart Stocks to Buy if a Recession Is on the Way
Here's why they picked Gilead Sciences (NASDAQ: GILD), Johnson & Johnson (NYSE: JNJ), and Vertex Pharmaceuticals (NASDAQ: VRTX). David Jagielski (Gilead Sciences): Investors can minimize their risk in the event of a recession by investing in businesses that provide essential products and services and that also pay a dividend to help offset declines in the event of dropping share prices. Gilead Sciences meets both of those criteria, as its HIV treatments are vital to patients.
- Motley Fool
The Best Stocks to Invest $5,000 In Right Now
The stock market has already marked its fair share of high highs and low lows in 2023, and we're not even a full month in. Vertex Pharmaceuticals (NASDAQ: VRTX) isn't one of those healthcare stocks with a massive portfolio of drugs that has tapped out its heyday of superior growth. At present, Vertex has just four approved drugs in its portfolio, and all of them treat the genetic disease cystic fibrosis.
